The Latest Breaking News from Celldex Therapeutics

Celldex shares slip 15% as safety concerns cloud skin drug trial win

(Rewrites throughout to add company comments, adds shares in paragraph 2, analyst comment in paragraph 5)- Celldex Therapeutics said on Tuesday its experimental

The Economic Times · Sep 22

2 ‘Strong Buy’ Growth Stocks With Upside of Around 200%

These growth stocks have the potential to dramatically outperform if you are willing to bear the risks.

Barchart · Jan 27

Celldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls Short

On Tuesday, Celldex Therapeutics, Inc. (NASDAQ:CLDX) released topline results from its ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus.

Benzinga · Aug 20, 2025